MediciNova Inc. (MNOV) and Mersana Therapeutics Inc. (NASDAQ:MRSN) Comparison side by side

This is a contrast between MediciNova Inc. (NASDAQ:MNOV) and Mersana Therapeutics Inc. (NASDAQ:MRSN) based on their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediciNova Inc. N/A 0.00 16.07M -0.42 0.00
Mersana Therapeutics Inc. 12.67M 11.62 55.79M -2.43 0.00

Table 1 demonstrates MediciNova Inc. and Mersana Therapeutics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of MediciNova Inc. and Mersana Therapeutics Inc.

Net Margins Return on Equity Return on Assets
MediciNova Inc. 0.00% -24.4% -23.1%
Mersana Therapeutics Inc. -440.33% -110.4% -49.8%

Liquidity

The Current Ratio and a Quick Ratio of MediciNova Inc. are 34.8 and 34.8. Competitively, Mersana Therapeutics Inc. has 2.9 and 2.9 for Current and Quick Ratio. MediciNova Inc.’s better ability to pay short and long-term obligations than Mersana Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors owned 24.5% of MediciNova Inc. shares and 86% of Mersana Therapeutics Inc. shares. Insiders owned 11.44% of MediciNova Inc. shares. Insiders Competitively, owned 0.1% of Mersana Therapeutics Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MediciNova Inc. -11.35% -27.38% -24.4% -4.33% 28.16% 36.48%
Mersana Therapeutics Inc. -2.26% -24.38% -63.29% -66.1% -67.63% -68.47%

For the past year MediciNova Inc. has 36.48% stronger performance while Mersana Therapeutics Inc. has -68.47% weaker performance.

Summary

MediciNova Inc. beats Mersana Therapeutics Inc. on 7 of the 9 factors.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company’s product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.